1-12 of 12
Katherine K. Matthay
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm Smith, Barry L. Shulkin, Marguerite Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2179–2189.
https://doi.org/10.1158/1078-0432.CCR-20-3909
Published: 15 April 2021
View article titled, Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032
Open the PDF for Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 in another window
Includes: Supplementary data
Journal Articles

Abstract A61: Evaluation of ctDNA in children with relapsed or refractory neuroblastoma treated with 131I-MIBG

David S. Shulman, Kelly Klega, Araz Marachelian, Katherine K. Matthay, Julie R. Park, M. Meaghan Granger, Steven G. DuBois, Brian D. Crompton
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A61.
https://doi.org/10.1158/1557-3265.LiqBiop20-A61
Published: 01 June 2020
View article titled, Abstract A61: Evaluation of ctDNA in children with relapsed or refractory neuroblastoma treated with 131I-MIBG
Journal Articles

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly Goldsmith, M. Meaghan Granger, Brian Weiss, Julie R. Park, Margaret E. Macy, Susan L. Cohn, Greg Yanik, Lars M. Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarzian, Hiroyuki Shimada, Najee Boucher, Scarlett Czarnecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K. Matthay, Araz Marachelian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6142–6149.
https://doi.org/10.1158/1078-0432.CCR-18-1381
Published: 13 December 2018
View article titled, Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group

Amy K. Erbe, Wei Wang, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonça, Yiqiang Song, Dustin Hess, Patrick K. Reville, Wendy B. London, Arlene Naranjo, Jacquelyn A. Hank, Mitchell B. Diccianni, Ralph A. Reisfeld, Stephen D. Gillies, Katherine K. Matthay, Susan L. Cohn, Michael D. Hogarty, John M. Maris, Julie R. Park, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu, Paul M. Sondel
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (1): 189–196.
https://doi.org/10.1158/1078-0432.CCR-17-1767
Published: 02 January 2018
View article titled, Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Open the PDF for Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group in another window
Includes: Supplementary data
Journal Articles

Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis

Araz Marachelian, Judith G. Villablanca, Cathy W. Liu, Betty Liu, Fariba Goodarzian, Hollie A. Lai, Hiroyuki Shimada, Hung C. Tran, Jaime A. Parra, Richard Gallego, Nora Bedrossian, Sabrina Young, Scarlett Czarnecki, Rebekah Kennedy, Brian D. Weiss, Kelly Goldsmith, Meaghan Granger, Katherine K. Matthay, Susan Groshen, Shahab Asgharzadeh, Richard Sposto, Robert C. Seeger
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5374–5383.
https://doi.org/10.1158/1078-0432.CCR-16-2647
Published: 14 September 2017
View article titled, Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis
Open the PDF for Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis in another window
Includes: Supplementary data
Journal Articles

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group

Kieuhoa T. Vo, Jeremy V. Edwards, C. Lorrie Epling, Elizabeth Sinclair, Douglas S. Hawkins, Holcombe E. Grier, Katherine A. Janeway, Phillip Barnette, Elizabeth McIlvaine, Mark D. Krailo, Donald A. Barkauskas, Katherine K. Matthay, Richard B. Womer, Richard G. Gorlick, Stephen L. Lessnick, Crystal L. Mackall, Steven G. DuBois
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (14): 3643–3650.
https://doi.org/10.1158/1078-0432.CCR-15-2516
Published: 14 July 2016
View article titled, Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group
Open the PDF for Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois, Susan Groshen, Julie R. Park, Daphne A. Haas-Kogan, Xiaodong Yang, Ethan Geier, Eugene Chen, Kathy Giacomini, Brian Weiss, Susan L. Cohn, M. Meaghan Granger, Gregory A. Yanik, Randall Hawkins, Jesse Courtier, Hollie Jackson, Fariba Goodarzian, Hiroyuki Shimada, Scarlett Czarnecki, Denice Tsao-Wei, Judith G. Villablanca, Araz Marachelian, Katherine K. Matthay
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2715–2721.
https://doi.org/10.1158/1078-0432.CCR-14-3240
Published: 14 June 2015
View article titled, Phase I Study of Vorinostat as a Radiation Sensitizer with <sup>131</sup>I-Metaiodobenzylguanidine (<sup>131</sup>I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Open the PDF for Phase I Study of Vorinostat as a Radiation Sensitizer with <sup>131</sup>I-Metaiodobenzylguanidine (<sup>131</sup>I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption

Katherine K. Matthay
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 311–313.
https://doi.org/10.1158/1078-0432.CCR-12-3313
Published: 16 January 2013
View article titled, Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption
Open the PDF for Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption in another window
Journal Articles

Promising Therapeutic Targets in Neuroblastoma

Katherine K. Matthay, Rani E. George, Alice L. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10): 2740–2753.
https://doi.org/10.1158/1078-0432.CCR-11-1939
Published: 14 May 2012
View article titled, Promising Therapeutic Targets in Neuroblastoma
Open the PDF for Promising Therapeutic Targets in Neuroblastoma in another window
Journal Articles

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Steven G. DuBois, Louis Chesler, Susan Groshen, Randall Hawkins, Fariba Goodarzian, Hiroyuki Shimada, Greg Yanik, Michael Tagen, Clinton Stewart, Yael P. Mosse, John M. Maris, Denice Tsao-Wei, Araz Marachelian, Judith G. Villablanca, Katherine K. Matthay
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2679–2686.
https://doi.org/10.1158/1078-0432.CCR-11-3201
Published: 30 April 2012
View article titled, Phase I Study of Vincristine, Irinotecan, and <sup>131</sup>I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Open the PDF for Phase I Study of Vincristine, Irinotecan, and <sup>131</sup>I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial in another window
Includes: Supplementary data
Journal Articles

Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma In Vitro and In Vivo Model Systems

Swati S. More, Melissa Itsara, Xiaodong Yang, Ethan G. Geier, Michelle K. Tadano, Youngho Seo, Henry F. VanBrocklin, William A. Weiss, Sabine Mueller, Daphne A. Haas-Kogan, Steven G. DuBois, Katherine K. Matthay, Kathleen M. Giacomini
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2339–2349.
https://doi.org/10.1158/1078-0432.CCR-10-2949
Published: 14 April 2011
View article titled, Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma <em>In Vitro</em> and <em>In Vivo</em> Model Systems
Open the PDF for Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma <em>In Vitro</em> and <em>In Vivo</em> Model Systems in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group

Kaci L. Osenga, Jacquelyn A. Hank, Mark R. Albertini, Jacek Gan, Adam G. Sternberg, Jens Eickhoff, Robert C. Seeger, Katherine K. Matthay, C. Patrick Reynolds, Clare Twist, Mark Krailo, Peter C. Adamson, Ralph A. Reisfeld, Stephen D. Gillies, Paul M. Sondel
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1750–1759.
https://doi.org/10.1158/1078-0432.CCR-05-2000
Published: 21 March 2006
View article titled, A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group
Open the PDF for A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group in another window